Philips

First Patient Treated with LC Bead LUMI™ Radiopaque Embolic Bead Supported by Philips Live Image Guidance

PhilipsBTG plc (LSE: BTG), a global specialist healthcare company, and Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in image-guided therapy, announced a significant milestone in their collaboration with the treatment of the first liver cancer patient with LC Bead LUMI™ in conjunction with Philips live image guidance, targeting a hypervascular tumor with the goal to block blood flow to achieve tumor necrosis.

Liver cancer is the second leading cause of cancer deaths in the world [1], and one of the most challenging to treat. Each year, more than 700,000 patients worldwide are diagnosed with liver cancer [2]. Interventional embolization is an option for some patients with tumors that cannot be removed by surgery.

The first patient treated signals the next stage in commercializing next generation embolic beads, which can be visualized during interventional procedures, allowing enhanced visualization to evaluate completeness of tumor treatment. As a result of the collaboration between BTG and Philips, for the first time doctors will be able to see rather than assume the location of the LC Bead LUMI™, in order to deliver their treatment with more confidence when treating liver cancer.

"The aim with this new radiopaque embolic bead and visualization technology is to provide clinicians like me the ability to make real-time adjustments while conducting the embolization procedure, so that we can optimize patients' treatment and hopefully improve targeting accuracy," said Bradford Wood, M.D., Director of the NIH Center for Interventional Oncology [3] and Chief of Interventional Radiology. "It is reassuring for the clinician and the patient to know that the treatment was delivered exactly where it was aimed, and where it was needed. Treating the first patient using LC Bead LUMI™ in combination with dedicated Philips 2D X-ray and 3D CBCT image guidance is a milestone in our public-private partnership with both of our industry research partners. The imaging of the beads during this first procedure was exquisite and provided valuable information."

By enabling visualization of beads during an embolization procedure, LC Bead LUMI™ will help embolization technology achieve its full potential. LC Bead LUMI™ has been developed with revolutionary radiopacity technology in collaboration with Philips that enables real-time visualization of bead location during embolization. LC Bead LUMI™, supported by Philips live image guidance, has the potential to offer interventional radiologists more control, allowing enhanced visualization to evaluate the completeness of tumor treatment and end-point determination.

"BTG continues to advance its leadership in Interventional Medicine by actively listening to our customers and providing creative solutions to meet their clinical needs," said Peter Pattison, Interventional Oncology General Manager, BTG. "Several years ago, we began scientific collaboration with Philips to evaluate the benefits of better image-guided therapy and this venture resulted in the ability to calibrate Philips' imaging software to LC Bead LUMI™. The clinical impact of the BTG-Philips collaboration is now helping interventional radiologists and multi-disciplinary teams make enhanced treatment decisions for patients with liver cancer."

"Minimally-invasive therapy procedures provide key benefits for healthcare systems and patients, and intelligent image guidance is an essential part of these procedures," said Ronald Tabaksblat, Business Leader Image Guided Therapy Systems at Philips. "We aim to continuously improve Image Guided Therapy and our collaboration with BTG to provide enhanced visibility and guidance during interventional embolization procedures is another important milestone in this exciting journey to help deliver excellent treatment and enhanced patient care."

LC Bead LUMI™ was cleared for clinical use in the US in December 2015 after extensive laboratory testing based on the clinical foundation of its predicate device, LC Bead®.

Related news articles:

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2015 sales of EUR 24.2 billion and employs approximately 104,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare.

About BTG Interventional Medicine
BTG Interventional Medicine is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavors to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots, and varicose veins.

About LC Bead LUMI™
LC Bead LUMI™ is the first commercially available radiopaque embolic bead cleared by the US Food & Drug Administration (FDA) for the embolization of hypervascular tumors and arteriovenous malformations (AVMs). LC Bead LUMI™ provides visible confirmation of bead location during AVM procedure. The lasting radiopacity of LC Bead LUMI™ means they will also be visible in follow-up scans.

1. World Health Organization (WHO). Cancer factsheet. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/. Last accessed January 25, 2016.
2. American Cancer Society. What are the key statistics about liver cancer?. Available at: http://www.cancer.org/cancer/livercancer/detailedguide/liver-cancer-what-is-key-statistics. Last accessed January 25, 2016.
3. NIH does not endorse or recommend any commercial products, processes, or services. The views and opinions of authors expressed here do not necessarily state or reflect those of the US Government or the NIH, and they may not be used for advertising or product endorsement purposes.

Most Popular Now

Philips and Spanish Hospital Campus…

Royal Philips (NYSE: PHG, AEX: PHIA) has announced the successful start of a long-term strategic partnership with Servicio Andaluz de Salud (Andalusian Health Service, Sp...

Read more

Artificial Intelligence may Aid in …

Machine learning is a type of artificial intelligence that allows computer programs to learn when exposed to new data without being programmed. Now, researchers in The Ne...

Read more

Your Wearable Devices Reveal Your P…

Wearable devices can give away your passwords, according to new research. In the paper "Friend or Foe?: Your Wearable Devices Reveal Your Personal PIN" scientists from Bi...

Read more

'Big Data' Study Discovers Earliest…

Scientists at the Montreal Neurological Institute and Hospital have used a powerful tool to better understand the progression of late-onset Alzheimer's disease (LOAD), id...

Read more

Study on the Impact of Marketing th…

The European Online Games, Social Media and Mobile Application sector has grown substantially in recent years and children are exposed to increasingly sophisticated marke...

Read more

Electronic Tablets Speed Stroke Car…

A clinical trial testing mobile videoconferencing as a means for physicians to diagnose stroke patients while they're being transported to the hospital has found that a t...

Read more

Can a Computer Game Train Your Brai…

That's the question Drexel University researchers hope to answer with one of two new studies launching this month. They have developed a computer game and smartphone app ...

Read more

Tackling Youth Obesity by Playing G…

Imagine a companion who is able to constantly motivate you, actively encourages you and changes your bad habits into healthy ones. A companion who is always present and w...

Read more

A 'Big Data' Approach to Developing…

Scientists are starting to accumulate huge datasets on which genes mutate during cancer, allowing for a more systematic approach to "precision medicine." In a study publi...

Read more

Nanotech 'Tattoo' can Map Emotions …

A new temporary "electronic tattoo" developed by Tel Aviv University that can measure the activity of muscle and nerve cells researchers is poised to revolutionize medici...

Read more

NHS Fife Wins Award after Cutting C…

NHS Fife has won a prestigious digital health award after frontline doctors and nurses have delivered rapid improvements in patient safety by harnessing an early warning ...

Read more

Informa Appoints Highland Marketing…

One the world's largest organisations for events, conferences and publishing has appointed Highland Marketing to manage communications at EHI Live 2016. Now in its 9th ye...

Read more

Digest Newsletter

Subscribe to our weekly Newsletter and stay updated on the latest eHealth News. Subscribe now, it's free!
© eHealthNews.eu 2006 - 2016